Pricing Log in Create free account

Neuphoria Therapeutics Inc. (NEUP) vs Pluri Inc. (PLUR)

Neuphoria Therapeutics Inc. and Pluri Inc. are both Biotechnology companies. Neuphoria Therapeutics Inc. and Pluri Inc. are of similar size ($15.0M and $15.0M). Neuphoria Therapeutics Inc. grew revenue faster over the last twelve months: 3,535.1% against −24.0%. Neuphoria Therapeutics Inc. has the higher net margin (0.00% vs −2,344.6%) and the higher return on invested capital (−232.7% vs −526.9%). Across the 17 metrics below, Neuphoria Therapeutics Inc. leads on 11 and Pluri Inc. on 6.

Valuation

Metric NEUP PLUR Biotechnology median
P/E n/m n/m 10.60
P/S 0.79 11.89 9.40
P/B 0.50 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.39 n/m 0.66
EV/Sales (0.42) 31.96 9.02
Earnings yield (180.00%) (197.58%) (32.88%)
Free cash flow yield (99.13%) (167.21%) (23.13%)

Profitability

Metric NEUP PLUR Biotechnology median
Gross margin 0.00% 44.59% 68.51%
Operating margin 0.00% (2,454.53%) 0.00%
Net margin 0.00% (2,344.59%) 0.00%
Free cash flow margin 0.00% (1,988.48%) 0.00%
Return on equity (61.70%) 260.35% (51.96%)
Return on assets (46.95%) (74.95%) (46.06%)
Return on invested capital (232.67%) (526.92%) 0.00%

Growth

Metric NEUP PLUR Biotechnology median
Revenue growth (TTM) 3,535.05% (23.95%) 6.76%
EPS growth (last fiscal year) (1,230.43%) 31.46% 29.88%
Revenue growth, 5-year CAGR 19.07% 113.32% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NEUP PLUR Biotechnology median
Debt to equity 0.00 (1.62) 0.00
Current ratio 27.85 0.27 4.97
Net debt to EBITDA 1.26 (0.83) 1.01

Dividend

Metric NEUP PLUR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric NEUP PLUR Biotechnology median
Market cap 14.99m 15.00m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack